BioStock: Chordate Medical secures entrance to Chinese market

Chordate Medical has renewed its joint venture agreement with Chinese medtech company Nanos Medical. The agreement concerns the jointly owned company Changyong Medical Technology, which will market Chordate Medical’s treatment method K.O.S for chronic nasal congestion in the Chinese market. Nanos Medical is now working to obtain a market license for the treatment in China, a process that is estimated to take about 16 months.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/chordate-medical-secures-entrance-to-chinese-market/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se